Bavarian Nordic
Clinical trials sponsored by Bavarian Nordic, explained in plain language.
Danish biotech company specializing in vaccines for infectious diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Mpox vaccine gets a production upgrade: new cell recipe under trial Results expected Nov 2026 (estimated)
- New vaccine aims to stop rare but deadly brain infections from mosquitoes Results expected Feb 2027 (estimated)
-
Massive vaccine trial aims to stop debilitating chikungunya virus
Vaccine Recruiting nowThis study tests a new vaccine to prevent chikungunya, a virus that causes fever and severe joint pain. About 6,144 people aged 12 and older will receive either the vaccine or a placebo. Researchers will check if the vaccine safely prevents infection and reduces long-term joint p…
Phase 3 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
New vaccine trial aims to protect kids from mosquito virus
Vaccine Recruiting nowThis study tests a vaccine against chikungunya virus in about 720 children aged 1 to under 12. The vaccine uses virus-like particles to train the immune system. Researchers will check if it is safe and triggers a strong immune response compared to a placebo.
Phase 3 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC